论文部分内容阅读
银杏叶入药始于明代,近十余年来,国内外医药学家对银杏叶的有效成分分析、制剂工艺、质量标准、检测方法以及临床应用等科学研究不断有新进展,取得新成果,不断加深理性化、科学化、现代化的新认识,因而进一步引起国际医药学界的异常关注。1998年卫生部批准上海中药研究所申报的二类新药并命名为“银杏酮酯”。笔者曾发表论文认为银杏酮酯应属国际银杏制剂的第五代产品,为治疗心脑血管等老年疾病效果较高、副反应较少、安全有效的又一种新
Ginkgo biloba leaves began to be used as medicine in the Ming Dynasty. In the past decade or so, domestic and foreign medical scientists have made new progress in scientific research on active ingredients, preparation techniques, quality standards, testing methods, and clinical applications of Ginkgo biloba, and achieved new results. Deepening the new understanding of rationalization, science, and modernization has further caused the abnormal concern of the international medical science community. In 1998, the Ministry of Health approved the second class of new drugs declared by the Shanghai Institute of Chinese Medicine and named it “Ginkgo Biloba Ester.” I have published a paper that Ginkgo biloba ketone should be the fifth generation of international ginkgo products, for the treatment of cardiovascular diseases such as geriatric diseases with high efficacy, fewer side effects, safe and effective and a new